Bayer AG Bids $2.4 Billion For Norwegian Cancer Drug Partner Algeta

Bayer (BAYGn.DE) has offered to pay $2.4 billion for Norway's Algeta (ALGETA.OL), its partner for a new prostrate cancer treatment, at a 27 percent premium to the stock's last close, Algeta said on Tuesday. The deal would boost Bayer's drugs division by giving it outright control over Xofigo, a drug the two have developed jointly since 2009 and started selling in the United States this year. Investors, however, bet that the German drugs and chemicals group has a fight on its hands and Algeta's Chief Financial Officer said that rival bids could not be ruled out.

Help employers find you! Check out all the jobs and post your resume.